

Clinical and molecular features of familial chronic lymphocytic leukemia: a pilot monocentric study

Giulia Benintende,^{1*} Idanna Innocenti,^{2*} Alberto Fresa,² Francesco Autore,² Annamaria Tomasso,¹ Alfonso Piciocchi,³ Florenzia Vuono,² Luca Stirparo,¹ Antonio Mosca,¹ Andrea Bacigalupo,¹ Valter Gattei,⁴ Dimitar Efremov,⁵ Eugenio Sangiorgi⁶ and Luca Laurenti¹

¹Sezione di Ematologia, Dipartimento di Scienze Radiologiche ed Ematologiche, Università Cattolica del Sacro Cuore, Rome; ²Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario “A. Gemelli” IRCCS, Rome; ³Data Center and Health Outcomes Research Unit, Italian Group for Adult Hematologic Disease (GIMEMA), Rome; ⁴Clinical Experimental Onco-Haematology Unit, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Aviano; ⁵Molecular Hematology, International Centre for Genetic Engineering & Biotechnology, Science Park Padriciano 99, Trieste and ⁶Sezione di Medicina Genomica, Dipartimento di Scienze della Vita e Sanità Pubblica, Università Cattolica del Sacro Cuore - Fondazione Policlinico Universitario “A. Gemelli” IRCCS, Rome, Italy

**GB and II contributed equally as first authors.*

Correspondence:

G. BENINTENDE - giuliabenintende97@gmail.com

<https://doi.org/10.3324/haematol.2022.282268>

<i>Characteristic</i>	<i>Sporadic CLL, N = 354</i>	<i>Familial CLL, N = 46</i>	<i>p-value</i>
Stage at diagnosis (Rai/Binet), n (%)			0.65
A/0	213 (47%)	19 (41%)	
A/I	63 (14%)	8 (17%)	
A/II	22 (4.8%)	3 (6.5%)	
B/I	13 (2.9%)	1 (2.2%)	
B/II	102 (22%)	11 (24%)	
C/III	8 (1.8%)	2 (4.3%)	
C/IV	15 (3.3%)	0 (0%)	
NA	18 (4.0%)	2 (4.3%)	
Lymphocytes (diagnosis), median (range)	11,000 (750, 335,110)	10,165 (1,930, 250,000)	0.90
Lymphocytes classes, n (%)			0.10
1 (<25.000)	345 (83%)	30 (79%)	
2 (25.000-50.000)	52 (12%)	4 (11%)	
3 (50.000-100.000)	14 (3.3%)	1 (2.6%)	
4 (>100.000)	7 (1.7%)	3 (7.9%)	
Beta2-MG (diagnosis), n (%)	108 (38%)	4 (18%)	0.11
IgG (diagnosis), median (range)	884 (184, 2,260)	991 (356, 2,320)	0.35
Splenomegaly, n (%)	123 (29%)	15 (36%)	0.46
Bulky lymph nodes, n (%)	20 (4.4%)	0 (0%)	0.29

Supplementary table 1: Clinical and hemato-chemical characteristics of familial vs sporadic CLL.

<i>Overall response</i>	<i>Yes</i>	<i>No</i>
Sporadic CLL	86.67%	13.33%
Familial CLL	68.42%	31.58%

Supplementary table 2: Overall response rate of familial vs sporadic CLL.